Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camonsertib + SBRT in Recurrent HNSCC
NCT07156227Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2027
- Primary completion
- May 2029
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camonsertib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events, Maximum tolerated dose and 1 more. Planned start Feb 2027; status: recruiting.
02
Drugs
camonsertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07156227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07156227.